These issues were illustrated also by a recent phase Ib/II study combining the selective MET-TKI capmatinib with gefitinib in the treatment of EGFRM+ NSCLC patients that had acquired resistance to EGFR-TKIs associated with MET-dysregulation [135]. The gene discussed is MET; the disease is non-small cell lung carcinoma.